First clinical trial data for new rabies vaccine candidate demonstrates promising immune response and safety

27 July 2022

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG. The RAB001 trial was conducted at the University and is the first time the novel rabies vaccine has been used in human volunteers.

The aim of the study was to look at safety and measure immune responses from the vaccine by analysing levels of rabies neutralising antibodies – a powerful marker of successful rabies vaccination.

In their findings (published in The Lancet Microbe), the researchers reported that 12 volunteers were recruited into the study in total, with three receiving a low dose, three receiving a medium dose and six receiving a high dose of ChAdOx2 RabG. Strong immune responses against rabies were generated by the vaccine, with all volunteers who received a medium or high dose developing levels of rabies neutralising antibodies above the World Health Organisation protective threshold (0.5 International Units / ml) within two months.

No serious adverse events or safety concerns were reported during the trial. Expected levels of common short-lived vaccine side effects such as soreness at the injection area or feverishness were observed in volunteers, mainly in the medium- and higher-dose groups.

Additionally, the researchers assessed longer term immune responses. Six of the seven middle- and high-dose recipients who returned for an additional follow-up one year after vaccination maintained neutralising antibody levels above the protective threshold, demonstrating that the immune response from the vaccine persists over time.

Associate Professor Sandy Douglas, Chief Investigator of the trial at the Jenner Institute, University of Oxford, said:
‘We’re absolutely delighted with these early results – the vaccine has performed even better than we had expected. The problems with existing rabies vaccines are that they are expensive and require multiple doses. We’re very hopeful that expanded trials in countries affected by rabies will prove that this new vaccine could enable routine, affordable, single-dose vaccination against this devastating disease for people living in such areas.’

Dr Daniel Jenkin, Lead Clinical Research Fellow of the trial at the Jenner Institute, University of Oxford, said:
‘New rabies vaccines based on modern vaccine technologies could become important tools in preventing the tens of thousands of rabies deaths that occur annually. Our strong early clinical trial data with ChAdOx2 RabG supports further development of this approach.’

The ChAdOx2 RabG vaccine is based on the ChAdOx2 vector – a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans, and is similar to the technology used successfully in the Oxford-AstraZeneca COVID-19 vaccine.

Researchers hope the promising results from the RAB001 trial will support further development of the vaccine and allow larger clinical trials to take place in the future. A Phase Ib/II clinical trial to assess safety and immunogenicity in Tanzania is also currently ongoing and results of that trial are expected later this year, with full results due in late 2023.

Notes for editors

Link to the paper (will only go live after embargo lifts) –
For further information, a copy of the paper or to request an interview with the researchers, please contact: [email protected] or call 01865 280528.

About the Jenner Institute
The Jenner Institute is based within the Nuffield Department of Medicine, University of Oxford, and is headquartered at the Old Road Campus Research Building, in Headington, Oxford. The Jenner Institute also supports senior vaccine scientists, known as Jenner Investigators, within many other departments across the University of Oxford, as well as externally within The Pirbright Institute and the Animal and Plant Health Agency.
The Jenner Institute brings together investigators who are designing and developing numerous vaccines to generate an exceptional breadth of scientific know-how and critical mass, whilst still allowing the individual investigators to remain independent and accountable to their funders and stakeholders.
The Jenner Institute is supported by the Jenner Vaccine Foundation, a UK registered charity and is advised by the Jenner Institute Scientific Advisory Board.

About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the sixth year running, and number 2 in the QS World Rankings 2022. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer.
Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full time jobs.